Carmot Therapeutics, Inc.
Clinical trials sponsored by Carmot Therapeutics, Inc., explained in plain language.
A biotech developing drugs for metabolic diseases like obesity.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New weekly shot shows promise for major weight loss
Disease control CompletedThis study tested a new drug called enicepatide (CT-388) given as a weekly injection for 48 weeks. It involved 469 adults with obesity or overweight who also had at least one weight-related health problem like high blood pressure or prediabetes. The goal was to see how much weigh…
Phase 2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New shot could help diabetics lose weight and lower blood sugar
Disease control CompletedThis study tested a new daily injection called CT-868 in 103 overweight or obese adults with type 2 diabetes. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if CT-868 could lower blood sugar levels (HbA1c) and help with weight loss.
Phase 2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New peptide drug shows promise for obesity and diabetes in early trial
Disease control CompletedThis early-stage trial tested a new drug called CT-388 in 129 overweight or obese adults, including some with type 2 diabetes. The study aimed to check the drug's safety and how the body processes it, while also measuring weight loss and blood sugar changes. Participants received…
Phase 1 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC